Business Context and Reporting Period
Company: NOVAVAX INC
Filing Type: Form 8-K (Current Report)
Report Date: November 18, 2003
Event Date: November 12, 2003 (Underwriting Agreement execution)
Key Financial Metrics
This filing reports a specific capital raising event rather than periodic financial performance metrics (e.g., revenue, profit, or cash flow from operations).
- Shares Sold: 4.5 million shares of common stock
- Offering Price: $6.15 per share
- Net Proceeds: Approximately $25.8 million (net of fees and expenses)
- Underwriter: C.E. Unterberg, Towbin
Material Changes
The Company entered into an Underwriting Agreement to sell 4.5 million shares of common stock. This transaction represents a significant increase in equity capital and liquidity for the Company. The shares were registered under a shelf registration statement (No. 333-108006).
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the transaction terms. The transaction was completed as announced in a press release dated November 18, 2003.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received versus the estimated $25.8 million.
- Review the attached Underwriting Agreement (Exhibit 1.1) for specific terms, lock-up periods, or indemnification clauses.
- Confirm the dilution impact of the 4.5 million new shares on existing shareholders.
- Check subsequent filings for the intended use of the raised capital.